Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational ...

Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...